A Phase 3 interventional study of DWP14012 20 mg and DWP14012 20 mg placebo in Healed Erosive Esophagitis, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-03.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Esophagitis with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Esophagitis · Korea, Republic of.
Among the 12 studies in Esophagitis with a site in Korea, Republic of, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2020, is one of 9 in phase 3, and was the 9th registered.
123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.
Browse Esophagitis studies →None of the 12 studies in Esophagitis with a site in Korea, Republic of is open now. The open studies under Esophagitis, anywhere →
Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 406 is above the median of 96 across 99 interventional studies indexed under Esophagitis.
Median enrollment 290 across the 12 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 6 most frequent:
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Daewoong Pharmaceutical Co. LTD. has 4 studies filed under Esophagitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Esophagitis with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after medication treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Orally, once daily
Drug: DWP14012 20 mg · Drug: Lansoprazole 15 mg Placebo
Orally, once daily
Drug: DWP14012 20 mg placebo · Drug: Lansoprazole 15 mg
DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 24
Time frame: at 24 week
Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 12
Time frame: at 12 week
GERD-Health related quality life(HRQL)
Changes from baseline in the total score of GERD-HRQL at Weeks 4, 12, and 24(The total score could range from 0 to 50 and lower score was evaluated as higher quality of life)
Time frame: at Weeks 4, 12, and 24
Assessment on symptoms
Proportions of subjects without the major symptoms (heartburn and/or acid regurgitation) at Weeks 4, 12, and 24
Time frame: Weeks 4, 12, and 24
Started Jul 2020 (actual). Primary completion is estimated for Aug 2021, 13 months after the start.
Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexuprazan
Daewoong Pharmaceutical Co. LTD. →